Jeevan Scientific Technology Ltd is Rated Sell

Understanding the Current Rating

The 'Sell' rating assigned to Jeevan Scientific Technology Ltd indicates a cautious stance for investors, suggesting that the stock may underperform relative to the broader market or sector peers. This rating is based on a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals. Each of these factors contributes to the overall assessment of the stock’s investment potential as of today.

Quality Assessment

As of 29 January 2026, the company’s quality grade remains below average. This reflects concerns about its long-term fundamental strength. Over the past five years, Jeevan Scientific Technology Ltd has experienced a significant decline in operating profits, with a compound annual growth rate (CAGR) of -204.41%. Such a steep contraction in profitability signals challenges in sustaining operational efficiency and growth momentum.

Additionally, the company’s average Return on Equity (ROE) stands at 9.56%, which is modest and indicates relatively low profitability generated per unit of shareholders’ funds. This level of ROE suggests that the company is not optimally leveraging its equity base to generate returns, which is a critical consideration for investors seeking quality growth stocks.

Valuation Considerations

Currently, the valuation grade for Jeevan Scientific Technology Ltd is classified as risky. The stock is trading at valuations that are considered elevated relative to its historical averages, raising concerns about the price investors are paying for the company’s earnings and growth prospects. Despite the stock delivering a 29.38% return over the past year as of 29 January 2026, this performance contrasts sharply with the company’s deteriorating profitability, which has fallen by approximately 450% during the same period.

This divergence between stock price appreciation and underlying profit decline suggests that the market may be pricing in expectations that are not yet supported by the company’s financial results, thereby increasing investment risk.

Financial Trend Analysis

The financial trend for Jeevan Scientific Technology Ltd is currently flat, indicating a lack of significant improvement or deterioration in recent financial performance. The latest quarterly results for September 2025 reveal a net loss, with the Profit After Tax (PAT) at Rs -0.09 crore, representing a sharp fall of 137.5%. This negative earnings trend is compounded by operational inefficiencies, as evidenced by the company’s inventory turnover ratio of 18.86 times, which is relatively low and may point to slower inventory movement or management challenges.

Moreover, the dividend payout ratio (DPR) remains at 0.00%, signalling that the company is not returning cash to shareholders, which may be a reflection of its constrained profitability and cash flow position.

Technical Outlook

From a technical perspective, the stock exhibits a mildly bullish grade. While this suggests some positive momentum in price action, it is not strong enough to offset the concerns raised by the fundamental and valuation assessments. The stock’s recent price movements show mixed signals, with a 6-month gain of 50.57% contrasting with a year-to-date decline of 7.71% and a one-month drop of 4.28% as of 29 January 2026.

These fluctuations indicate volatility and uncertainty in investor sentiment, which may be influenced by broader market conditions or sector-specific developments within healthcare services.

Stock Performance Summary

As of 29 January 2026, Jeevan Scientific Technology Ltd’s stock performance presents a mixed picture. While the one-year return of 29.38% is notable, shorter-term returns have been negative, including a 3.75% decline over the past week and a 2.46% drop over three months. This volatility underscores the importance of a cautious approach, especially given the company’s underlying financial challenges.

What the 'Sell' Rating Means for Investors

The 'Sell' rating from MarketsMOJO serves as a cautionary signal for investors considering Jeevan Scientific Technology Ltd. It suggests that the stock currently carries elevated risks due to weak fundamental quality, risky valuation, flat financial trends, and only mild technical support. Investors should be aware that the company’s financial health and profitability metrics do not currently justify a more optimistic outlook.

For those holding the stock, this rating encourages a reassessment of portfolio exposure, weighing the potential for further downside against any strategic reasons for maintaining the position. Prospective investors may prefer to monitor the company’s financial recovery and valuation adjustments before committing capital.

Sector and Market Context

Operating within the healthcare services sector, Jeevan Scientific Technology Ltd faces sector-specific challenges and opportunities. While healthcare remains a critical and growing industry, individual company performance can vary widely based on operational efficiency, innovation, and market positioning. The microcap status of the company also implies higher volatility and liquidity considerations compared to larger peers.

Investors should consider these factors alongside the company’s current rating and financial profile when making investment decisions.

Conclusion

In summary, Jeevan Scientific Technology Ltd’s 'Sell' rating as of 13 Nov 2025 reflects a comprehensive evaluation of its current financial and market position as of 29 January 2026. The company’s below-average quality, risky valuation, flat financial trend, and mildly bullish technicals collectively inform this cautious stance. Investors are advised to carefully analyse these factors in the context of their investment objectives and risk tolerance.

Continued monitoring of the company’s financial performance and market developments will be essential to reassess this rating in the future.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →